Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

18.40 +0.44 (+2.45%)
Streaming Delayed Price Updated: 12:10 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
News headline image
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds ↗
The company is soon to seek regulatory approval in the U.S. and abroad. 
Via Investor's Business Daily
News headline image
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
News headline image
Navigating 5 Analyst Ratings For NovoCure ↗
 
Via Benzinga
News headline image
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
News headline image
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
News headline image
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
News headline image
Why NovoCure Stock Dived by 13% This Week ↗
Investors found the announced changes to the company's C-suite unsettling. 
Via The Motley Fool
News headline image
Beyond The Numbers: 4 Analysts Discuss NovoCure Stock ↗
 
Via Benzinga
News headline image
NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
News headline image
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips ↗
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
News headline image
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients ↗
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant... 
Via Benzinga
News headline image
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment ↗
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
News headline image
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
News headline image
Novocure Announces Planned CEO Transition
From Novocure
Via Business Wire
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
From Novocure
Via Business Wire
News headline image
Chips, Glorious Chips! ↗
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
News headline image
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.